Archive for July 11th, 2012

HGSI PDUFA date set. NVS AdCom September. OGXI to initiate Phase 3 NSCLC later this year + NKTR GEVA OSUR offering details

Jul 11, 2012 No Comments by

Human Genome Sciences, Inc. (Nasdaq: HGSI) announced the FDA has assigned a PDUFA date of December 15, 2012 for the resubmission of the Biologics License Application (BLA) for raxibacumab, a treatment for inhalational anthrax. The resubmission follows a complete response letter, which was received on November 14, 2009. The Anti-Infective Drugs Advisory Committee will meet on September 5, 2012, to discuss the new […]

Daily News Read more